Victoria Socha

DocwireNews

Patients on hemodialysis often develop anemia due to hypoerythropoiesis and chronic inflammation. The hormone <a href="https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-021-02426-7">hepcidin</a> regulates iron homeostasis and is an indicator of iron deficiency in patients with end-stage kidney disease. Masateru Yamamoto and colleagues in Japan conducted a study designed to examine the effects of increased blood flow rate (BFR) during hemodialysis on serum hepcidin levels and <a href="https://www.docwirenews.com/nephtimes/nephtimes-diseases-and-conditions/anemia/anemia-in-ckd-projected-to-increase-15-by-2025/">anemia</a> [BMC Nephrology. doi.org/10.1186/s12882-021-02426-7].Between April 2014 and March 2016, the study enrolled 22 patients undergoing maintenance hemodialysis treatment three times a week. The patients were followed prospectively for 14 months. Of the 22 patients, 11 were men and mean age was 72 years. In April 2014, the BFR was 200 mL/min; BFR was increased to 400 mL/min in 2015. The dialysate flow rate was stable at 500 mL/min. The primary end point of interest was the comparison of the amounts of erythropoiesis-stimulating agent (ESA) required.The increased BFR increased total kidney volume and was associated with a significant decrease in urea nitrogen (P=.015) and creatinine (P=.005) levels. Increasing the BFR improved the dialysis efficiency. Further, there were significant reductions in ferritin, hepcidin, and high -sensitivity interleukin-6 levels (P=.038, P=.041, and P=.038, respectively). There was significant reduction in the ESA administered (P=.004) and significant improvement in the Erythropoietin Resistant Index (ERI) (P=.031).Compared to rates of reduction in urea nitrogen, creatinine, and beta-2 microglobulin prior to the BFR increase, reduction rates after the BFR increase were significantly greater. There was no effect on hepcidin related to the BFR change.In conclusion, the researchers said, &ldquo;Increasing BFR was associated with hemodialysis efficiency, and led to reduce inflammatory cytokine interleukin-6, but did not contribute to reduce C-reactive protein. This reduced hepcidin levels, ESA dosage, and ERI. Hepcidin levels were significantly correlated with ferritin levels, and it remains to be seen whether reducing hepcidin leads to improve ESA and iron availability during anemia management.&rdquo;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Anemia and Hepcidin Concentration in Hemodialysis Patients

Anemia and Kidney Disease

Patients on hemodialysis often develop anemia due to hypoerythropoiesis and chronic inflammation. The hormone hepcidin regulates iron homeostasis and is an indicator of iron ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe